CORPS & PSYCHISME
P-ISSN: 2496-4476 E-ISSN: 2273-1571
Volume 13/ Issue 1/ 2026

Targeted Drug Delivery Using Stimuli-Responsive Polymeric Nanocarriers

Dr. Elena V. Markovic
Department of Pharmaceutical Nanotechnology, Institute of Biomaterials and Drug Delivery Systems, University of Belgrade, Serbia

Received : 26/08/2025 ; Accepted : 17/12/2025 ; Published : 15/03/2026

Abstract
Modern nanomedicine relies on customized drug delivery technologies to boost therapeutic efficacy and reduce systemic toxicity. Stimuli-responsive polymeric nanocarriers can release therapeutic drugs in reaction to internal or external triggers, allowing spatiotemporal drug delivery control. These smart devices deliver drugs selectively using physiological cues like pH gradients, redox potential, enzyme activity, and hypoxia in sick tissues and external stimuli like temperature, magnetic fields, ultrasound, and light. Amphiphilic block copolymers, dendrimers, and hydrogels, which self-assemble into micelles, vesicles, and nanoparticles, have been designed with specific physicochemical features thanks to polymer chemistry. Active targeting ligands including antibodies, peptides, and aptamers boost site-specific accumulation and strengthen the enhanced permeability and retention (EPR) effect. Stimuli-responsive polymeric nanocarriers boost drug bioavailability, diminish multidrug resistance, and improve cancer, inflammatory, and neurological disease treatment outcomes in recent preclinical and clinical trials. To implement these technologies in clinical practice, scalability, repeatability, biocompatibility, and regulatory approval must be addressed.
Keywords: Stimuli-responsive polymers; targeted drug delivery; polymeric nanocarriers; smart nanomedicine

Introduction

Pharmaceutical researchers have long sought safe and effective drug delivery systems to optimize therapeutic efficacy while minimizing systemic toxicity and side effects, which typically limit conventional medicines' clinical success. Oral and intravenous medication administration often has low bioavailability, quick clearance, non-specific distribution, and lack of release kinetics control, which can lead to underperformance and patient non-compliance. Nanomedicine has revolutionized drug delivery by using nanoscale carriers to improve precision, stability, and efficiency. Polymeric nanocarriers are one of the most flexible and intensively studied classes due to their biocompatibility, customizable physicochemical properties, and capacity to encapsulate tiny molecules, proteins, peptides, and nucleic acids. Over the past two decades, researchers have focused on designing stimuli-responsive polymeric nanocarriers, also known as “smart” or “intelligent” systems, which can respond to specific internal or external stimuli to control drug release at the target site. In accordance with precision medicine, this method increases therapeutic drug concentration in sick tissues and lowers off-target effects and systemic toxicity. Stimuli-responsive nanocarriers use diseased site microenvironments or external triggers to be selective and controllable. Cancer and

inflammation, when the local environment differs from healthy tissues, benefit from internal stimuli including pH, redox potential, enzyme activity, and hypoxia. The acidic pH of tumor microenvironments and endo/lysosomal compartments can break down acid-labile links or protonate polymers, allowing controlled medication release where it is needed. Tumor cells' high glutathione levels provide a redox-sensitive environment that cleaves nanocarrier disulfide bonds, releasing encapsulated medicines intracellularly. Enzyme-responsive carriers degradation in the presence of disease-specific enzymes such matrix metalloproteinases allow selective release in sick tissues while protecting healthy organs. Clinicians can non-invasively and temporally modulate external stimuli for precision control. Light-responsive polymers that change structure when irradiated, ultrasound-sensitive carriers that release drugs when acoustic cavitation occurs, magnetic field-responsive nanoparticles guided to target tissues, and thermosensitive polymers that exploit local hyperthermia all add control to drug delivery. Multiple stimuli in a nanocarrier design provide multi-triggered release profiles that respond to endogenous and external inputs, increasing the flexibility of these systems. These intelligent carriers are engineered using polymer chemistry, which allows exact medication loading, stability, and responsiveness. Amphiphilic block copolymers self-assemble into micelles and vesicles with hydrophobic cores that enclose poorly soluble medicines and hydrophilic shells that stabilize and stealth. Dendrimers' highly branched structures and abundant functional groups enable high drug-loading and tailored surface modifications, while hydrogels' three-dimensional polymer networks can encapsulate and release large biomolecules under specific stimuli. Polymer modularity allows surface functionalization with targeting ligands like antibodies, peptides, aptamers, and small molecules, which enable active and passive targeting through the enhanced permeability and retention (EPR) effect used in tumor tissues. Functionalization permits nanocarriers to selectively concentrate in sick locations and engage specific cellular receptors for receptor-mediated endocytosis and intracellular drug delivery.

Internal Stimuli-Responsive Nanocarriers

One intriguing family of smart drug delivery technologies is internal stimuli-responsive polymeric nanocarriers, which use the specific microenvironmental circumstances of sick tissues to accomplish controlled and exact medication release. These nanocarriers are designed to selectively react to endogenous cues like pH gradients, redox potential, enzyme activity, and hypoxia, ensuring localized drug accumulation while minimizing systemic toxicity. This is in contrast to conventional carriers that passively or non-specifically release drugs. The idea behind these designs comes from the physiological differences between healthy and diseased tissues. Tumors and inflamed areas, for example, have a pH that is acidic, higher levels of reducing agents like glutathione, specific enzymes that are overexpressed, and microenvironments that are oxygen-deprived. Internal stimuli-responsive nanocarriers with improved therapeutic efficacy and less off-target effects have been produced by researchers by incorporating stimuli-sensitive links, polymers, or surface changes.

pH-Responsive Systems

The acidic conditions found in solid tumors (pH 6.5-6.9), inflammatory tissues, and intracellular compartments like endosomes and lysosomes (pH 4.5-6.0) are utilized by pH-responsive nanocarriers. Polymeric nanocarriers that have acid-labile linkages or pH-sensitive polymers remain stable at physiological pH (~7.4) but degrade or protonate in acidic environments, causing the release of the drug. Examples of acid-labile linkages include hydrazone, acetal, imine, or orthoester bonds. pH-sensitive polymers include poly(histidine), poly(β-amino esters), or polyacrylic acid. Micelles loaded with doxorubicin and connected by hydrazone bonds have shown that the medicine can be selectively released into tumor tissues while remaining stable in the bloodstream. To further facilitate drug release in acidic intracellular compartments, protonation of ionizable polymers can trigger structural changes or swelling of nanogels. By improving intracellular transport of chemotherapeutics, this method not only boosts site-specificity but also ensures effective cytotoxicity against cancer cells by overcoming lysosomal sequestration.

Redox-Responsive Carriers

Utilizing the notable disparities in redox potential between external fluids and the intracellular environment, redox-responsive nanocarriers take advantage of the elevated glutathione (GSH) levels in cancer cells' cytoplasm (2-10 mM) as contrasted with plasma (2-20 μM). Polymers engineered with disulfide (-S-S-) or diselenide (-Se-Se-) bonds in their backbones, as crosslinkers, or as drug-polymer connections take advantage of this gradient. Rapid drug release into target cells and carrier destabilization result from cleavage of these bonds under reducing circumstances. One example is the anticancer efficacy and effective intracellular release of paclitaxel encapsulated in polymeric micelles that have been crosslinked by disulfide. Therapeutic biomolecules that need to be released into the cell nucleus to have an impact, like peptides, DNA, or siRNA, are best delivered by redox-sensitive devices. To improve therapeutic efficacy, decrease off-target toxicity, and guarantee selective intracellular release, redox-responsive nanocarriers are utilized.

Enzyme-Sensitive Polymers

Highly targeted to diseased tissues, enzyme-responsive nanocarriers either disintegrate or undergo transformation in reaction to enzymes that are overexpressed in pathological states. Matrix metalloproteinases (MMPs) and cathepsins are often overexpressed in cancerous tumor microenvironments. These enzymes can release medications selectively at tumor sites by cleaving specific peptide sequences embedded in polymer backbones or linkers. For example, polymeric micelles that contain MMP-cleavable peptide linkers have shown that they may disassemble tumors specifically and release drugs, which greatly enhances their ability to prevent tumor growth. A similar mechanism is at work in cancers and inflammatory tissues, where hyaluronidase enzymes are often overexpressed; these enzymes can destroy hyaluronidase-sensitive carriers, enabling the targeted release of encapsulated medicines. Disease-specific enzymes serve as natural medication release triggers in enzyme-sensitive systems, which have applications outside of cancer, for example, in arthritic conditions and bacterial infections. This method bridges the gap between diagnosis and treatment by increasing selectivity via the activation of nanocarriers in relation to illness biomarkers.

Hypoxia-Activated Nanocarriers

As a result of insufficient blood flow and fast cell division, hypoxia, or low oxygen levels, characterizes numerous solid tumors and ischemic tissues. To take advantage of this property, hypoxia-responsive nanocarriers incorporate moieties that reduce in low-oxygen environments, causing structural changes or bond cleavage that initiate drug release. Such designs often make use of quinone-based polymers, azobenzene linkers, and nitroimidazole derivatives. The destabilization of the nanocarrier and the enhancement of drug release in oxygen-deficient tissues are caused by the reduction of these groups to hydrophilic derivatives under hypoxic conditions. For instance, in hypoxic tumor areas where conventional medications are ineffective because of low penetration and resistance, hypoxia-activated micelles containing doxorubicin or siRNA have shown to accumulate selectively and have strong therapeutic benefits. When combined with imaging agents for theranostic applications, hypoxia-triggered devices open up new possibilities for combination therapy, allowing for the simultaneous diagnosis and treatment of hypoxic malignancies.

Conclusion

Innovative stimuli-responsive polymeric nanocarriers have the potential to revolutionize targeted drug delivery by providing clinicians with smart platforms that can detect and react to specific internal and external stimuli found in diseased tissues, allowing for the controlled and localized release of therapeutics. These systems allow for the spatiotemporal precision of drug administration by utilizing endogenous cues like pH gradients, redox potential, enzymatic activity, and hypoxia in addition to external stimuli like temperature, light, ultrasound, and magnetic fields. This reduces systemic toxicity and enhances therapeutic efficacy. Thanks to developments in polymer chemistry, various architectures such as hydrogels, nanogels, vesicles, dendrimers, and micelles have been developed. These structures can encapsulate various drugs and can be fine-tuned for different purposes by adding degradable linkages and modifying chemical properties. Complementing the increased permeability and retention effect, the incorporation of targeted ligands like antibodies, aptamers, and peptides has resulted in even greater selectivity, guaranteeing preferential accumulation at disease locations. This nanocarrier technology shows great potential in the field of oncology, inflammatory illnesses, and neurological disorders. Preclinical studies have shown that these nanocarriers can significantly improve medication bioavailability, intracellular transport, and the ability to overcome multidrug resistance. Nevertheless, in order to implement these smart systems in clinical practice, there are still obstacles to overcome regarding reproducibility, biocompatibility, long-term safety, regulatory approval, and large-scale production. Integrating them with state-of-the-art methods like theranostics, gene therapy, immunotherapy, and AI-driven nanocarrier design will undoubtedly expand their influence and speed up personalized treatment in the future. The future of precision drug delivery systems is bright, and stimuli-responsive polymeric nanocarriers are a prime example of this. They bring together nanotechnology and clinical therapies, and they could revolutionize the way we treat some of the most difficult diseases we face today.

References

Akhtar, M. F., Hanif, M., & Ranjha, N. M. (2016). Methods of synthesis of hydrogels … A review. *Saudi Pharmaceutical Journal*, *24*(5), 554–559. https://doi.org/10.1016/j.jsps.2015.03.022

Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017). Rethinking cancer nanotheranostics. *Nature Reviews Materials*, *2*(7), 17024. https://doi.org/10.1038/natrevmats.2017.24

Cui, J., Yan, Y., Such, G. K., Liang, K., Ochs, C. J., Postma, A., & Caruso, F. (2012). Stimuli-responsive polymer capsules for drug delivery and imaging. *Accounts of Chemical Research*, *45*(7), 1015–1024. https://doi.org/10.1021/ar200282n

Gao, W., Hu, C. M. J., Fang, R. H., Luk, B. T., Su, J., & Zhang, L. (2013). Surface functionalization of gold nanoparticles with red blood cell membranes. *Journal of the American Chemical Society*, *135*(27), 9974–9977. https://doi.org/10.1021/ja404465n

Guo, J., Yu, Z., Das, M., Huang, L., & Wang, L. (2020). Stimuli-responsive polymeric nanocarriers for efficient drug delivery and cancer therapy. *Acta Pharmaceutica Sinica B*, *10*(5), 1035–1049. https://doi.org/10.1016/j.apsb.2020.01.009

Jin, Q., Deng, Y., Chen, X., Ji, J., & Shen, J. (2019). Smart polymeric nanocarriers for cancer therapy. *Nano Today*, *28*, 100767. https://doi.org/10.1016/j.nantod.2019.100767

Kanwal, U., Bukhari, N. I., Rana, N. F., Rehman, M., Hussain, K., Abbas, N., & Mehmood, A. (2019). Stimuli-responsive polymeric nanocarriers for targeted drug delivery applications. *European Journal of Pharmaceutical Sciences*, *132*, 122–141. https://doi.org/10.1016/j.ejps.2019.02.019

Kumar, R., Kulkarni, A., Nagesha, D., Sridhar, S., & Priyadarsini, K. I. (2016). Synthesis and applications of stimuli-responsive polymeric nanocarriers for drug delivery. *Journal of Controlled Release*, *235*, 147–164. https://doi.org/10.1016/j.jconrel.2016.06.030